Milestones 2017-06-13T00:23:15+00:00

Emerald Health Sciences’ rapid growth is testament to the ability of its leadership to create value by leveraging long-standing relationships and experience to attract expertise and accumulate assets that support its vision.


1H Emerald Health Sciences incorporated


1H Acquired control of a Canadian licensed producer authorized by Health Canada to produce, sell and carry out research and development on medical cannabis
1H Acquisition of 10% of VivaCell, a preclinical-stage pharmaceutical company focused on the development of NCEs derived from cannabidiols
1H Acquisition of a series of CDB derived novel NCEs from VivaCell and continuing their pre-clinical development


1H Entered into a drug discovery collaboration with University of Eastern Piedmont in Italy

2016 Target

2H Execute agreement to acquire control of VivaCell

2017 Target

1H Initiate bioceutical product sales

2018 Target

1H Submit clinical trial application (IND in the US and/or CTA in Europe)
1H Build out complete of 100,000 sf production facility